BNGO
Bionano Genomics, Inc.
There isn't enough reported data to score BNGO yet.
BNGO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Weak | |
| Unavailable |
BNGO's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
BNGO PE Valuation
BNGO has no meaningful PE right now: it lost money over the past year.
BNGO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| -- |
Analysts expect BNGO's losses to shrink, with revenue growing.
BNGO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2024 | -$150.60 | +$267.00 |
| Q2 2024 | -$312.60 | -$22.20 |
| Q1 2024 | -$372.60 | -$90.60 |
| Q4 2023 | -$408.60 | -$132.60 |
| Q3 2023 | -$417.60 | -$171.60 |
| Q2 2023 | -$290.40 | -$68.40 |
| Q1 2023 | -$282.00 | -$84.00 |
| Q4 2022 | -$276.00 | -$120.00 |
BNGO is still losing money, but far less than before: $150.60 per share over the past year, against $417.60 at its worst in late 2023.
BNGO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $8.3M | +12% |
| Q2 2026 | $8.2M | +21% |
| Q1 2026 | $6.7M | +3.6% |
| Q4 2025 | $8M | -2.6% |
| Q3 2025 | $7.4M | +21% |
| Q2 2025 | $6.7M | -13% |
| Q1 2025 | $6.5M | -26% |
| Q4 2024 | $8.2M | -24% |
BNGO's revenue is recovering but still below its 2023 peak: $8M last quarter, up 12% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -79% | +37 points |
| Q2 2026 | -88% | +28 points |
| Q1 2026 | -118% | +13 points |
| Q4 2025 | -107% | +39 points |
| Q3 2025 | -116% | +607 points |
| Q2 2025 | -116% | +103 points |
| Q1 2025 | -131% | +224 points |
| Q4 2024 | -146% | +87 points |
BNGO's operating margin was −79% last quarter, up 37 points from the same quarter a year ago, near the top of its range since 2019.
BNGO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$4.5M | +$1.4M |
| Q2 2026 | -$4.7M | -$1.2M |
| Q1 2026 | -$5.7M | -$3M |
| Q4 2025 | -$4.2M | +$2.3M |
| Q3 2025 | -$5.9M | +$7.4M |
| Q2 2025 | -$3.5M | +$17.5M |
| Q1 2025 | -$2.8M | +$25.4M |
| Q4 2024 | -$6.5M | +$23.3M |
BNGO has burned cash in almost every quarter: −$19M over the past year, against −$19M the year before.
BNGO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +445K shares |
| 1 year | +248% | +8.6M shares |
| 3 years | +2388% | +11.5M shares |
| 5 years | +5312% | +11.8M shares |
BNGO has 12M diluted shares, up 248% from a year ago.
BNGO Net Leverage
BNGO's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
BNGO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 39.2 | Neutral |
| Stochastic | 8.2 | Oversold |
BNGO's weekly RSI is 39 (neutral) and its Stochastic is 8 (oversold).
BNGO PE vs Healthcare Sector
BNGO has no meaningful PE right now: it lost money over the past year.
BNGO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.29 | 19% below |
| 20 week MA | $1.24 | 16% below |
| 50 week MA | $1.27 | 18% below |
| 100 week MA | $2.86 | 64% below |
| 200 week MA | $112.3 | 99% below |
BNGO is in a downtrend: it's below all five of its weekly moving averages, and 99% below its 200-week average.
BNGO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $648.0 | $423.0 | -35% |
| 2021 | $423.0 | $1,944.0 | +360% |
| 2022 | $1,944.0 | $912.0 | -53% |
| 2023 | $912.0 | $113.4 | -88% |
| 2024 | $113.4 | $12.6 | -89% |
| 2025 | $12.6 | $1.52 | -88% |
| 2026 YTD | $1.52 | $1.04 | -32% |
BNGO has finished four years in a row lower, and it's down 32% so far in 2026.